ImmunityBio, Inc. IBRX Product revenue, net — Total Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s product revenue, net — total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s product revenue, net — total revenue?
- ImmunityBio, Inc. (IBRX) reported product revenue, net — total revenue of $44.17M in Q1 2026.
- How has ImmunityBio, Inc.'s product revenue, net — total revenue changed year-over-year?
- ImmunityBio, Inc.'s product revenue, net — total revenue increased by 167.5% year-over-year, from $16.51M to $44.17M.
- What does product revenue, net — total revenue mean?
- This metric represents the total net revenue generated specifically from the sale of commercialized pharmaceutical or biotechnology products. It excludes non-product income such as licensing fees, research grants, or collaborative development payments. This figure serves as a primary indicator of the company's transition from a clinical-stage research entity to a commercial-stage enterprise.